 "Qure.ai secures M funding to expand AI health solutions globally, revolutionizing diagnosis and treatment in critical diseases.")
Qure.ai, an innovative healthtech company based in Mumbai, has successfully raised $65 million in a Series D funding round. This investment will help accelerate its expansion into the U.S. and other markets, improve its foundational AI models, and support potential acquisitions in the med-tech space. Founded in 2016, Qure.ai aims to make healthcare more accessible worldwide with its AI-driven solutions, which are currently used in over 3,000 locations across 90 countries. CEO Prashant Warier highlights the company’s commitment to enhancing clinical efficiency and patient care, especially in critical areas like TB, lung cancer, and stroke. The funding round included participation from major investors like Lightspeed and Merck, further solidifying Qure.ai’s position in the healthcare sector.
Qure.ai Secures $65 Million in Series D Funding to Expand AI Healthcare Solutions
Qure.ai, an innovative healthtech company focused on using artificial intelligence to improve healthcare, has successfully raised $65 million in its Series D funding round. This funding will allow the company to accelerate its expansion into the United States and other markets, invest further in foundational AI technology, and consider acquiring complementary medical technology firms.
The Series D round saw notable contributions from new investors including Lightspeed and 360 ONE Asset, along with established participants like Merck Global Health Innovation Fund and Kae Capital. Returning investors such as Novo Holdings, Health Quad, and TeamFund also supported this fundraising effort.
Founded in 2016 and based in Mumbai, Qure.ai aims to make healthcare more accessible and equitable worldwide. Its AI solutions currently operate in over 90 countries and more than 3,000 healthcare facilities. The company has regional offices located in New York, London, and Dubai.
Prashant Warier, CEO and co-founder of Qure.ai, commented on the company’s mission: “We are a medical imaging AI partner to hospitals and healthcare organizations globally. Our technology aims to improve clinical efficiency and enhance patient care in critical areas like tuberculosis, lung cancer, and stroke.” He emphasized that AI helps address challenges in healthcare such as imaging report delays, low screening rates, and workforce shortages, applicable not only in developed nations but also in developing areas.
Qure.ai collaborates with many top pharmaceutical and medtech companies, including AstraZeneca, Medtronic, and Johnson & Johnson, to enhance early diagnosis and timely treatment for various diseases. Warier noted, “This Series D funding marks an important step towards our goal of reaching one billion patients with our solutions.”
Dev Khare from Lightspeed remarked on Qure.ai’s impact, stating that the company is making high-quality healthcare accessible in not just the US and Europe but also across Asia, Africa, and Latin America. Tarun Sharma from 360 ONE Asset emphasized the transformative potential of Qure.ai’s work, especially in early diagnosis and treatment of high-mortality diseases like lung cancer.
As Qure.ai continues on its journey, the recent funding will significantly enhance its ability to provide AI-driven healthcare solutions globally.
Tags: Qure.ai, funding, healthcare technology, AI in healthcare, Series D funding, Prashant Warier, diagnostics, tuberculosis, lung cancer, medical innovation
-
What is Qure.ai?
Qure.ai is a healthcare technology company that uses artificial intelligence to help analyze medical images, making it easier for doctors to diagnose diseases. -
How much money did Qure.ai raise in its recent funding round?
Qure.ai raised 65 million dollars in its Series D funding round. -
What will Qure.ai do with the new funding?
Qure.ai plans to use the new funding to improve its technology, expand its team, and reach more healthcare providers around the world. -
Why is this funding round important for Qure.ai?
This funding round is important because it allows Qure.ai to grow and develop its AI tools, helping more patients get better and faster care. - Who invested in Qure.ai during this funding round?
Several investors participated in the funding round, including existing investors and new partners who believe in the company’s mission and technology.
